FDA to Expedite Review of Teva Drug for Movement Disorder FDA to Expedite Review of Teva Drug for Movement Disorder
Israel-based Teva Pharmaceutical Industries said on Tuesday the U.S. Food and Drug Administration (FDA) has granted"priority review" for its SD-809 drug to treat tardive dyskinesia with a target date for approval by Aug. 30.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
FDA to expedite review of Teva drug for movement disorder
"There remains a significant unmet medical need in tardive dyskinesia," said Michael Hayden, chief scientific officer at Teva. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 28, 2017 Category: Pharmaceuticals Source Type: news
FDA to expedite review of Teva drug for movement disorder
TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday the U.S. Food and Drug Administration (FDA) has granted "priority review" for its SD-809 drug to treat tardive dyskinesia with a target date for approval by Aug. 30. (Source: Reuters: Health)
Source: Reuters: Health - February 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Poorly tuned neuronal communication may underlie neurological and psychiatric disease
(JCI Journals) In this issue of the JCI, Nils Brose and colleagues at the Max Planck Institute for Experimental Medicine have identified a mutation in a synaptic protein called UNC13 in a patient diagnosed with ASD, hyperactivity, and dyskinesia. Further investigation revealed that the UNC13 mutation disturbs the fine-tuning of neuronal communication at the level of the synapse. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 13, 2017 Category: Global & Universal Source Type: news
Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 6, 2017 Category: Drugs & Pharmacology Source Type: news
Neurocrine Provides Update on FDA Advisory Committee for Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia
SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the Ingrezza (valbenazine) New Drug Application (NDA), has decided to... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 5, 2017 Category: Drugs & Pharmacology Source Type: news
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia
SAN DIEGO, Nov. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Neurocrine Biosciences, Inc. (NBIX) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in the... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2016 Category: Pharmaceuticals Source Type: news
Neurocrine Announces FDA Advisory Committee Meeting to Review Ingrezza (valbenazine) NDA for the Treatment of Tardive Dyskinesia
SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in the New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 29, 2016 Category: Drugs & Pharmacology Source Type: news
Once-Daily Oral Med May Reduce Levodopa-Induced Dyskinesia Once-Daily Oral Med May Reduce Levodopa-Induced Dyskinesia
A once-daily extended-release medication may rapidly improve levodopa-induced dyskinesia, a major clinical issue in patients with Parkinson ' s disease, new research shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Objectively assessed physical activity and its association with balance, physical function and dyskinesia in Parkinson's disease - Nero H, Benka-Wall én M, Franzén E, Conradsson D, Ståhle A, Hagstromer M.
BACKGROUND: The desirable effects of physical activity in individuals with Parkinson's disease are well-known, although according to results from previous studies factors associated with objectively assessed physical activity are not fully investigated. ... (Source: SafetyLit)
Source: SafetyLit - September 10, 2016 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 29, 2016 Category: Drugs & Pharmacology Source Type: news
Why brain neurons in Parkinson's disease stop benefiting from levodopa
Though the drug levodopa can dramatically improve Parkinson ' s disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition -- involuntary repetitive, rapid and jerky movements. UAB researchers have uncovered an essential mechanism of long-term memory for L-DOPA-induced-dyskinesia: widespread reorganization of DNA methylation, and this may be a therapeutic target to prevent or reverse dyskinesia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 28, 2016 Category: Science Source Type: news
Why brain neurons in Parkinson's disease stop benefiting from levodopa
( < i > University of Alabama at Birmingham < /i > ) Though the drug levodopa can dramatically improve Parkinson's disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition -- involuntary repetitive, rapid and jerky movements. UAB researchers have uncovered an essential mechanism of long-term memory for L-DOPA-induced-dyskinesia: widespread reorganization of DNA methylation, and this may be a therapeutic target to prevent or reverse dyskinesia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 28, 2016 Category: Global & Universal Source Type: news
Valbenazine Reduces Tardive Dyskinesia, With Good TolerabilityValbenazine Reduces Tardive Dyskinesia, With Good Tolerability
In the phase 3 KINECT 3 trial, investigational drug valbenazine reduced tardive dyskinesia among psychiatric patients receiving antipsychotic medications, with a favorable safety profile. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 30, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Long-Acting Drug Safe in Dyskinesia (CME/CE)
(MedPage Today) -- Extended-release amantadine well tolerated over 41 weeks (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 23, 2016 Category: Geriatrics Source Type: news
